Founded on a contrarian thesis: that the next decade of enterprise AI will be won by the engineering discipline around the models — not the models themselves.
We hire people who’ve shipped at scale — not people whose strongest skill is the PowerPoint. Domain SMEs who understand the work being automated. Engineers who keep recipes, evals, and guardrails portable. That’s the team you actually get.
Avira was founded on a contrarian observation: enterprise AI was about to face the same gap enterprise software faced twenty years ago. Plenty of vendors selling capability. Almost nobody bridging that capability to production — to systems that survive compliance, run in real cloud environments, and adapt as the technology underneath keeps changing.
The companies that won the last era of enterprise tech weren’t the ones with the cleverest products. They were the ones with the engineering discipline to make those products actually work inside large organizations. We’re betting the same will be true here.
So Avira sits in an unusual position: at the confluence of software and services. A bespoke product portfolio and an enterprise-grade engineering practice. Not because we couldn’t pick one — but because the gap we’re closing requires both.
America’s fastest-growing private companies. Listed twice, four years apart — across two distinct phases of growth.
Major Contender — Life Sciences Digital Services Specialist. Recognized twice running for vertical depth.
Active in MAPS, MASS, and pharma medical-affairs forums. Partner ecosystem with Veeva, Salesforce, IBM, and IQVIA.
Three phases. The work compounded into the practice we are today.
We addressed complex digital, data, and analytics needs for life sciences and financial services clients. Custom application development, UI/UX, integration, cloud engineering. We learned what enterprise actually means — and saw, repeatedly, where good projects went to die.
Partnerships with AppOrchid and NNIT extended our reach. We invested heavily in data integration and cloud lifecycle work. And we began the slow turn toward productizing what we kept rebuilding by hand.
Focused investment in life sciences. Launch of the proprietary product suite — E360, M360, and the AI-driven social-monitoring solution that became Insight360°. Key F500 pharma wins. Expanded relationships with Veeva, Salesforce, and IBM. A strategic GTM partnership with IQVIA.
Featured in the Inc. 5000 in 2023 and 2025. Recognized in Everest Group’s PEAK Matrix in 2024 and 2025. The thesis began to pay off — clients started buying the productized version of what was previously a custom build.
Mature E360 and M360 platforms. Launch of Athena — our internal workbench for agentic-AI delivery. Multiple RFPs, POCs, and account expansions across F500 life-sciences and financial-services clientele. Early traction in the sports vertical with 8+ POCs running.
The path ahead: expand the recipe library, deepen our coexistence model with hyperscalers, and become the engineering partner CIOs mention by name when they say their AI program works.
We do not just build agents. We help enterprises get them into the right environment, adapt them quickly after go-live, and stabilize them so they make a measurable difference in the business.
Avira’s team is built around three disciplines: domain SMEs who understand the work being automated (pharma medical affairs, financial payments, sports intelligence), AI engineers who ship production agents, and platform engineers who keep the underlying recipes, evals, and guardrails portable.
We hire people who’ve shipped at scale — not people whose strongest skill is the PowerPoint. The Architecture Decision Records you receive from us are written by the engineers who built the system, not by a delivery layer between you and them.
Avira is an active voice in the medical-affairs conversation — not a sponsor on the back of a lanyard.
Active participation at Medical Affairs Professional Society (MAPS) and Medical Affairs Strategic Summit (MASS). Recurring panels alongside medical-affairs leaders from J&J, Amgen, GSK, and Pfizer. Two ongoing podcast series with practicing leaders.
Active participation at Medical Affairs Professional Society (MAPS) and Medical Affairs Strategic Summit (MASS) — the two forums that set the agenda for our primary vertical.
Founder and CEO Sanjeev Welling is a recurring panel participant alongside medical-affairs leaders from J&J, Amgen, GSK, and Pfizer at industry events focused on the future of evidence and insight.
Two ongoing podcast series with leading medical-affairs experts on the future of insight-driven decision making and the agentic enterprise.
Not because we sold them a platform. Because we shipped the work that proved it. The recipe library expands. The coexistence model deepens. The verticals stay deep, not wide. And our clients keep their optionality — because in the long run, that’s the only thing worth building toward.
Tell us about a problem you’re trying to solve. We’ll be honest about whether we’re the right partner — and if not, who is.